Last-Resort drug offered for patients with untreatable infections
NCT ID NCT04334070
Summary
This program provides access to the drug Clofazimine for adults with serious Non-Tuberculous Mycobacterial (NTM) infections that have not responded to standard treatments. The drug is approved for leprosy but is being made available here for patients who have run out of other options. Doctors can request it for eligible patients when standard therapies have failed or caused severe side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-TUBERCULOUS MYCOBACTERIAL (NTM) INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.